Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.

About this episode

This episode features an interview with Thomas von Erlach, Ph.D., discussing Vivtex's innovative approach to developing orally available biologics.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas s...

People in this episode

Host: Ben Comer

Guests: Thomas von Erlach, Ph.D., Thomas von Erlach

Topics covered

• biologics
• oral drugs
• obesity
• diabetes
• biotechnology

Keywords

• biologics
• oral availability
• Vivtex
• Novo Nordisk
• obesity
• diabetes
• biotechnology
• Langer Lab
• MIT

Mentioned in this episode

Organizations: Vivtex, Novo Nordisk

Places: MIT

More episodes of Business Of Biotech

• The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry · June 8, 2026 · 1h 24m
• Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D. · June 1, 2026 · 50 min
• Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane · May 25, 2026 · 55 min
• Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D. · May 18, 2026 · 51 min
• Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D. · May 11, 2026 · 54 min
• From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D. · May 4, 2026 · 56 min